4010 N-terminal domain in beta subunit of DNA dependent RNA-polymerase
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 5 | 6.8 | 0.74× | q = 0.51 | |
| Phenylpropanoids and polyketides | 6 | 0.3 | 21× | not tested | |
| Benzenoids | 3 | 1.0 | 2.97× | not tested | |
| Lipids and lipid-like molecules | 4 | 1.5 | 2.60× | not tested | |
| Organoheterocyclic compounds | 3 | 2.1 | 1.41× | not tested | |
| Organic oxygen compounds | 3 | 2.8 | 1.09× | not tested | |
| Nucleosides, nucleotides, and analogues | 4 | 3.8 | 1.05× | not tested | |
| Organic acids and derivatives | 2 | 2.1 | 0.94× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB01045 | RFP | Rifampin | 14 |
| DB02596 | APC | alpha,beta-Methyleneadenosine 5'-triphosphate | 6 |
| DB04137 | GTP | Guanosine-5'-Triphosphate | 6 |
| DB04785 | STD | Streptolydigin | 6 |
| DB03403 | C5P | Cytidine-5'-Monophosphate | 5 |
| DB00171 | ATP | ATP | 4 |
| DB03532 | G2P | Phosphomethylphosphonic acid guanylate ester | 4 |
| DB00615 | RBT | Rifabutin | 2 |
| DB01201 | RPT | Rifapentine | 2 |
| DB02431 | CTP | Cytidine-5'-Triphosphate | 2 |
| DB04457 | DGP | 2'-Deoxyguanosine-5'-Monophosphate | 2 |
| DB00131 | AMP | Adenosine phosphate | 1 |
| DB03170 | COD | Dephospho Coenzyme A | 1 |
| DB03258 | DCP | 2'-Deoxycytidine 5'-triphosphate | 1 |
| DB04005 | UTP | Uridine 5'-triphosphate | 1 |
| DB04672 | D4M | Cyclic 3',5'-thymidine monophosphate | 1 |
| DB14128 | NAD | Nadide | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| 1N7 | CHAPSO | 24 |
| MGmetal | MAGNESIUM ION | 16 |
| RFP | RIFAMPICIN | 14 |
| SRN | SORANGICIN A | 6 |
| STD | STREPTOLYDIGIN | 6 |
| GTP | GUANOSINE-5'-TRIPHOSPHATE | 5 |
| ZNmetal | ZINC ION | 5 |
| 2TM | 5'-O-[(S)-hydroxy{[(S)-hydroxy(phosphonooxy)phosphoryl]methyl}phosphoryl]cytidine | 4 |
| 4QM | (3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-10,13-dimethyl-17-[(2R)-pentan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol | 4 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 4 |
| B4P | BIS(ADENOSINE)-5'-TETRAPHOSPHATE | 4 |
| KNG | Kanglemycin A | 4 |
| A1IF9 | [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [[[(2~{R},3~{S},4~{R},5~{R})-5-(2-azanyl-6-oxidanylidene-1~{H}-purin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]oxy-oxidanyl-phosphoryl] hydrogen phosphate | 3 |
| MB8 | (2Z)-2-methylbut-2-enoic acid | 3 |
| 1RL | Benzoxazinorifamycin-2b | 2 |
| 1RM | Benzoxazinorifamycin-2c | 2 |
| 42S | N'-hydroxy-N-phenyl-3-(trifluoromethyl)benzenecarboximidamide | 2 |
| 42T | 3-{[(2,6-dichlorophenyl)carbamoyl]amino}-N-hydroxy-N'-phenyl-5-(trifluoromethyl)benzenecarboximidamide | 2 |
| 42U | 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(piperazin-1-yl)ethyl]-2-(trifluoromethyl)aniline | 2 |
| 4OB | N-hydroxy-N'-phenyl-3-(trifluoromethyl)benzenecarboximidamide | 2 |